When both IRF1 and IRF2 were absent, type I IFN treatment could not restore MHC I expression or reverse resistance to CPI, confirming the concept that type I IFN can induce IRF1 and restore immunogenicity of the tumor cells and host cytotoxic response to them. The gene discussed is IRF1; the disease is neoplasm.